EU agency backs Novartis' Afinitor in breast cancer
Key points
- European regulators on Friday recommended approval of a Novartis' for the treatment of advanced breast cancer.
- The Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for Afinitor in patients with HER2 - advanced breast cancer in combination with exemestane.
- Afinitor, which is already approved for other types of cancer such as kidney and a rare type of pancreatic cancer, will now go to the European Commission for formal approval, a process that normally takes a couple of months.
- Novartis says there are around 220,000 newly diagnosed cases worldwide each year of the type of advanced breast cancer that could benefit from Afinitor.
European regulators on Friday recommended approval of a Novartis' for the treatment of advanced breast cancer.
The Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for Afinitor in patients with HER2 - advanced breast cancer in combination with exemestane.
Afinitor, which is already approved for other types of cancer such as kidney and a rare type of pancreatic cancer, will now go to the European Commission for formal approval, a process that normally takes a couple of months.
Novartis says there are around 220,000 newly diagnosed cases worldwide each year of the type of advanced breast cancer that could benefit from Afinitor.
###
(Reuters)
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsNeoadjuvant use of pertuzumab in HER2-positive breast cancer
Pertuzumab (trade name: Perjeta) is approved for two therapeutic indications. Its use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable…
4 December 2015
NewsCancer survivors less likely to receive callbacks from potential employers
Job applicants who are cancer survivors are less likely to receive callbacks from potential retail employers than those who did not disclose their health history, according to a recent study by Rice University and Penn…
7 November 2015
NewsPotential new therapy for triple-negative breast cancer shows promise in lab studies
Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult to treat and aggressive form of the disease. In a recent study…
